Literature DB >> 21735095

Protein kinase CK2 accumulation in "oncophilic" cells: causes and effects.

Maria Ruzzene1, Kendra Tosoni, Sofia Zanin, Luca Cesaro, Lorenzo A Pinna.   

Abstract

At variance with protein kinases expressed by oncogenes, CK2 is endowed with constitutive activity under normal conditions, and no CK2 gain-of-function mutants are known. Its amount, however, is abnormally high in malignant cells where it appears to be implicated in many of the cell biology phenomena associated with cancer. These observations can be reconciled assuming that tumor cells develop an overdue reliance ("non-oncogene addiction") on abnormally high CK2 level. While the potential of this latter to generate an environment favorable to neoplasia is consistent with the global antiapoptotic and prosurvival role played by CK2, it is not clear what is determining accumulation of CK2 in cells "predisposed" to become malignant. Exploiting the apoptosis sensitive (S) or resistant (R) CEM cell model, characterized by sharply different CK2 levels, we have now correlated the level and degradation rate of CK2 to those of the chaperone proteins Hsp90 and Cdc37. We show in particular that persistence of high CK2 level in R-CEM, as opposed to S-CEM, is accompanied by the presence of an immunospecific form of Cdc37 not detectable in S-CEM and refractory to staurosporine-induced degradation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735095     DOI: 10.1007/s11010-011-0959-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  20 in total

1.  Unique activation mechanism of protein kinase CK2. The N-terminal segment is essential for constitutive activity of the catalytic subunit but not of the holoenzyme.

Authors:  Stefania Sarno; Paola Ghisellini; Lorenzo A Pinna
Journal:  J Biol Chem       Date:  2002-04-15       Impact factor: 5.157

Review 2.  The protein kinase complement of the human genome.

Authors:  G Manning; D B Whyte; R Martinez; T Hunter; S Sudarsanam
Journal:  Science       Date:  2002-12-06       Impact factor: 47.728

3.  Assessment of CK2 constitutive activity in cancer cells.

Authors:  Maria Ruzzene; Giovanni Di Maira; Kendra Tosoni; Lorenzo A Pinna
Journal:  Methods Enzymol       Date:  2010       Impact factor: 1.600

4.  Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.

Authors:  G Di Maira; F Brustolon; J Bertacchini; K Tosoni; S Marmiroli; L A Pinna; M Ruzzene
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

Review 5.  Addiction to protein kinase CK2: a common denominator of diverse cancer cells?

Authors:  Maria Ruzzene; Lorenzo A Pinna
Journal:  Biochim Biophys Acta       Date:  2009-08-06

Review 6.  Protein kinase CK2 signal in neoplasia.

Authors:  S Tawfic; S Yu; H Wang; R Faust; A Davis; K Ahmed
Journal:  Histol Histopathol       Date:  2001-04       Impact factor: 2.303

7.  Functional polymorphism of the CK2alpha intronless gene plays oncogenic roles in lung cancer.

Authors:  Ming-Szu Hung; Yu-Ching Lin; Jian-Hua Mao; Il-Jin Kim; Zhidong Xu; Cheng-Ta Yang; David M Jablons; Liang You
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

8.  Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia.

Authors:  Jin Seok Kim; Ju In Eom; June-Won Cheong; Ae Jin Choi; Jin Koo Lee; Woo Ick Yang; Yoo Hong Min
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

9.  Non-oncogene addiction and the stress phenotype of cancer cells.

Authors:  Nicole L Solimini; Ji Luo; Stephen J Elledge
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

Review 10.  Natural product origins of Hsp90 inhibitors.

Authors:  Yoshimasa Uehara
Journal:  Curr Cancer Drug Targets       Date:  2003-10       Impact factor: 3.428

View more
  8 in total

1.  Co-expressions of casein kinase 2 (CK2) subunits restore the down-regulation of tubulin levels and disruption of microtubule structures caused by PrP mutants.

Authors:  Zhao-Yun Wang; Qi Shi; Shao-Bin Wang; Chan Tian; Ying Xu; Yan Guo; Cao Chen; Jin Zhang; Xiao-Ping Dong
Journal:  J Mol Neurosci       Date:  2012-07-01       Impact factor: 3.444

Review 2.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

Review 3.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

4.  Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.

Authors:  Sofia Zanin; Christian Borgo; Cristina Girardi; Sean E O'Brien; Yoshihiko Miyata; Lorenzo A Pinna; Arianna Donella-Deana; Maria Ruzzene
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

Review 5.  Therapeutic targeting of CK2 in acute and chronic leukemias.

Authors:  F Buontempo; J A McCubrey; E Orsini; M Ruzzene; A Cappellini; A Lonetti; C Evangelisti; F Chiarini; C Evangelisti; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2017-09-27       Impact factor: 11.528

6.  Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor.

Authors:  Karsten Niefind; Nils Bischoff; Andriy G Golub; Volodymyr G Bdzhola; Anatoliy O Balanda; Andriy O Prykhod'ko; Sergiy M Yarmoluk
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-11

Review 7.  Exploring the CK2 Paradox: Restless, Dangerous, Dispensable.

Authors:  Cinzia Franchin; Christian Borgo; Silvia Zaramella; Luca Cesaro; Giorgio Arrigoni; Mauro Salvi; Lorenzo A Pinna
Journal:  Pharmaceuticals (Basel)       Date:  2017-01-20

8.  Synthesis and properties of a selective inhibitor of homeodomain-interacting protein kinase 2 (HIPK2).

Authors:  Giorgio Cozza; Sofia Zanin; Renate Determann; Maria Ruzzene; Conrad Kunick; Lorenzo A Pinna
Journal:  PLoS One       Date:  2014-02-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.